Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study

Duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ and -γ, was evaluated in a Phase 1 study in advanced hematologic malignancies, which included expansion cohorts in relapsed/refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and treat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Hematol
Main Authors: O’Brien, Susan, Patel, Manish, Kahl, Brad S., Horwitz, Steven M., Foss, Francine M., Porcu, Pierluigi, Jones, Jeffrey, Burger, Jan, Jain, Nitin, Allen, Kerstin, Faia, Kerrie, Douglas, Mark, Stern, Howard M., Sweeney, Jennifer, Kelly, Patrick, Kelly, Virginia, Flinn, Ian
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8260004/
https://ncbi.nlm.nih.gov/pubmed/30094870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25243
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados